Streetbeat News

Products Services

CLVT

Clarivate Plc (NYSE: CLVT) announced that Daikin Industries has selected its IPfolio product to enhance operational efficiency.

Portfolio Pulse from

November 27, 2024 | 8:15 am

AGYTF

Allergy Therapeutics has started a phase III trial to test the safety and effectiveness of its Grass MATA MPL allergy treatment in children, marking the first industry trial of its kind for pediatric patients with grass pollen-induced allergic rhinitis.

Portfolio Pulse from

November 27, 2024 | 8:00 am

VLERF

Valeura Energy Inc. has successfully completed an infill drilling campaign at the Jasmine field in the Gulf of Thailand, which is expected to enhance production.

Portfolio Pulse from

November 27, 2024 | 7:45 am

QBTS

The article discusses the potential of D-Wave Quantum's Leap platform in the quantum computing sector, highlighting its reliable quantum annealing system and significant industry clients. The integration of the Advantage2 processor and the National Quantum Initiative Act reauthorization are seen as catalysts for share price growth.

Portfolio Pulse from

November 27, 2024 | 7:30 am

VLE

Valeura Energy Inc. has successfully completed an infill drilling campaign at the Jasmine field, offshore Gulf of Thailand, resulting in oil production rates of nearly 10,000 bbls/d.

Portfolio Pulse from

November 27, 2024 | 7:15 am

AGNMF

Agronomics Limited's portfolio company, All G Co, has received regulatory approval to sell recombinant bovine lactoferrin in China, marking a significant milestone in the field of cellular agriculture.

Portfolio Pulse from

November 27, 2024 | 7:15 am

BNO

Geopolitical tensions and OPEC+ discussions are influencing the prices of WTI and Brent crude oil. Key levels, demand shifts, and inventory trends are crucial factors in shaping these price trends.

Portfolio Pulse from

November 27, 2024 | 7:00 am

NVS

Novartis has received European Commission approval for Kisqali® in combination with an aromatase inhibitor for treating HR+/HER2- early breast cancer at high risk of recurrence.

Portfolio Pulse from

November 27, 2024 | 6:30 am

C

Citigroup is in the early stages of a turnaround, with stable revenue but declining profitability due to investments in technology and human capital. These investments are expected to boost EPS significantly by 2030. The company's valuation is attractive, with low P/E and P/B ratios compared to peers.

Portfolio Pulse from

November 27, 2024 | 6:30 am

BOND

SGOV

SGOV's attractiveness is reduced due to expected Federal Reserve rate cuts, which may lower its distribution. While SGOV remains a stable cash equivalent, its future returns are limited. Broader bond funds like PIMCO's BOND may offer better returns by leveraging declining rates and longer maturities.

Portfolio Pulse from

November 27, 2024 | 6:30 am